Table 4.
Overall and subgroup analysis for relation between XRCC1 rs25487 and side effects.
| Comparison | Group | Subgroup | No. Patients | No. Study | OR | 95% CI | P value | Heterogeneity | Effect model |
|---|---|---|---|---|---|---|---|---|---|
| AA vs GG | Overall | 5333 | 57 | 1.05 | 0.90–1.23 | 0.525 | 44.5% | Fixed | |
| Acute/Late | Late | 1795 | 22 | 0.81 | 0.62–1.07 | 0.139 | 3.6% | Fixed | |
| Acute | 2950 | 31 | 1.29 | 0.90–1.85 | 0.168 | 53.0% | Random | ||
| Cancer | Breast cancer | 1538 | 11 | 0.85 | 0.55–1.31 | 0.462 | 53.9% | Random | |
| Head and neck cancer | 1642 | 26 | 1.04 | 0.77–1.42 | 0.780 | 16.8% | Fixed | ||
| Prostate cancer | 688 | 5 | 0.88 | 0.51–1.52 | 0.656 | 0.0% | Fixed | ||
| Non-small cell lung cancer | 799 | 9 | 1.07 | 0.57–2.00 | 0.833 | 44.5% | Fixed | ||
| Cutoff | Grade ≥2 | 3777 | 42 | 1.06 | 0.88–1.28 | 0.523 | 46.1% | Fixed | |
| Grade ≥3 | 820 | 8 | 0.98 | 0.59–1.62 | 0.943 | 46.5% | Random | ||
| Side effects | Skin toxicity | 1558 | 17 | 0.84 | 0.63–1.13 | 0.259 | 46.9% | Fixed | |
| Soft tissue injury | 803 | 8 | 0.75 | 0.51–1.11 | 0.151 | 47.4% | Fixed | ||
| Mucositis | 579 | 9 | 1.30 | 0.78–2.16 | 0.310 | 0.0% | Fixed | ||
| Treatment | RT | 2164 | 18 | 1.03 | 0.63–1.68 | 0.905 | 66.9% | Random | |
| RCT | 746 | 14 | 1.86 | 1.25–2.77 | 0.002 | 0.0% | Fixed | ||
| RT+RCT | 1383 | 16 | 0.87 | 0.60–1.26 | 0.463 | 22.1% | Fixed | ||
| GA vs GG | Overall | 7732 | 57 | 1.17 | 1.05–1.30 | 0.004 | 40.4% | Fixed | |
| Acute/Late | Late | 2660 | 22 | 1.00 | 0.83–1.20 | 0.985 | 22.4% | Fixed | |
| Acute | 4248 | 31 | 1.29 | 1.12–1.48 | 0.001 | 47.3% | Fixed | ||
| Cancer | Breast cancer | 2369 | 11 | 1.07 | 0.89–1.28 | 0.470 | 13.9% | Fixed | |
| Head and neck cancer | 2194 | 26 | 1.25 | 1.03–1.52 | 0.025 | 45.2% | Fixed | ||
| Prostate cancer | 1161 | 5 | 1.03 | 0.73–1.44 | 0.885 | 0.0% | Fixed | ||
| Non-small cell lung cancer | 1066 | 9 | 1.09 | 0.84–1.43 | 0.526 | 10.7% | Fixed | ||
| GA vs GG | Cutoff | Grade ≥2 | 5472 | 42 | 1.19 | 1.05–1.35 | 0.006 | 29.2% | Fixed |
| Grade ≥3 | 1208 | 8 | 1.47 | 0.86–2.50 | 0.162 | 63.1% | Random | ||
| Side effects | Skin toxicity | 2249 | 17 | 1.10 | 0.91–1.33 | 0.347 | 19.0% | Fixed | |
| Soft tissue injury | 1171 | 8 | 1.07 | 0.66–1.72 | 0.796 | 57.9% | Random | ||
| Mucositis | 781 | 9 | 1.70 | 1.13–2.55 | 0.011 | 31.6% | Fixed | ||
| Treatment | RT | 3198 | 18 | 1.27 | 1.08–1.49 | 0.003 | 50.0% | Fixed | |
| RCT | 1036 | 14 | 1.23 | 0.94–1.61 | 0.134 | 47.6% | Fixed | ||
| RT+RCT | 1853 | 16 | 1.11 | 0.88–1.39 | 0.390 | 43.2% | Fixed | ||
| GA+AA vs GG | Overall | 10200 | 67 | 1.18 | 1.07–1.30 | 0.001 | 48.8% | Fixed | |
| Acute/Late | Late | 3278 | 23 | 0.93 | 0.79–1.10 | 0.401 | 23.7% | Fixed | |
| Acute | 5953 | 40 | 1.42 | 1.17–1.73 | 0.000 | 50.6% | Random | ||
| Cancer | Breast cancer | 3469 | 18 | 1.03 | 0.88–1.20 | 0.738 | 9.6% | Fixed | |
| Head and neck cancer | 2526 | 26 | 1.19 | 0.99–1.43 | 0.068 | 49.9% | Fixed | ||
| Prostate cancer | 1310 | 5 | 1.00 | 0.72–1.38 | 0.985 | 0.0% | Fixed | ||
| Non-small cell lung cancer | 1298 | 9 | 1.13 | 0.89–1.45 | 0.319 | 25.8% | Fixed | ||
| Cutoff | Grade ≥2 | 6566 | 45 | 1.15 | 1.03–1.29 | 0.013 | 47.3% | Fixed | |
| Grade ≥3 | 2311 | 15 | 1.57 | 1.07–2.30 | 0.020 | 52.2% | Random | ||
| Side effects | Skin toxicity | 2719 | 19 | 1.06 | 0.89–1.27 | 0.498 | 26.7% | Fixed | |
| Soft tissue injury | 1579 | 9 | 0.92 | 0.60–1.41 | 0.706 | 61.4% | Random | ||
| Mucositis | 902 | 9 | 1.52 | 1.13–2.06 | 0.006 | 27.2% | Fixed | ||
| Treatment | RT | 3913 | 20 | 1.23 | 0.95–1.61 | 0.119 | 62.5% | Random | |
| RCT | 2163 | 21 | 1.55 | 1.25–1.92 | 0.000 | 39.7% | Fixed | ||
| RT+RCT | 2214 | 17 | 1.07 | 0.86–1.32 | 0.548 | 45.3% | Fixed |
RCT, radio-chemotherapy; RT, radiotherapy.
The bold values mean that they are statistically significant.